Granules India Limited — Updates, 12-08-2025: Press Release

Granules India reported Q1FY26 financial results: Revenue grew 3% YoY to ₹1,210.1 Cr, but EBITDA declined 5% to ₹246.7 Cr and PAT dropped 16% to ₹112.6 Cr. Sales growth was led by North America. Operational highlights include successful USFDA audits across multiple facilities with minor observations and EU GMP certification for Gagillapur. The company generated strong cash flow of ₹280.6 Cr. Integration of Senn Chemicals through the Ascelis platform is set to drive CDMO growth, and formulations growth trajectory is expected to resume. Net debt stands at ₹948.0 Cr (0.96x EBITDA).